351 related articles for article (PubMed ID: 8913454)
1. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
Tankovic J; Perichon B; Duval J; Courvalin P
Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
[TBL] [Abstract][Full Text] [Related]
2. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
3. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
4. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
[TBL] [Abstract][Full Text] [Related]
5. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
Taba H; Kusano N
Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
[TBL] [Abstract][Full Text] [Related]
6. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
Janoir C; Zeller V; Kitzis MD; Moreau NJ; Gutmann L
Antimicrob Agents Chemother; 1996 Dec; 40(12):2760-4. PubMed ID: 9124836
[TBL] [Abstract][Full Text] [Related]
7. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
8. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
Varon E; Janoir C; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
[TBL] [Abstract][Full Text] [Related]
9. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
10. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
Muñoz R; De La Campa AG
Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
[TBL] [Abstract][Full Text] [Related]
11. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.
Janoir C; Podglajen I; Kitzis MD; Poyart C; Gutmann L
J Infect Dis; 1999 Aug; 180(2):555-8. PubMed ID: 10395882
[TBL] [Abstract][Full Text] [Related]
12. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
13. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Pan XS; Ambler J; Mehtar S; Fisher LM
Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
[TBL] [Abstract][Full Text] [Related]
14. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
17. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
18. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
20. Primary targets of fluoroquinolones in Streptococcus pneumoniae.
Fukuda H; Hiramatsu K
Antimicrob Agents Chemother; 1999 Feb; 43(2):410-2. PubMed ID: 9925547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
